BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32319631)

  • 1. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma.
    Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
    Mol Med Rep; 2020 Apr; 21(4):1849-1860. PubMed ID: 32319631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
    Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
    Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
    Shrestha R; Bridle KR; Cao L; Crawford DHG; Jayachandran A
    Curr Oncol; 2021 Jun; 28(3):2150-2172. PubMed ID: 34208001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-370 Regulates Cellepithelial-Mesenchymal Transition, Migration, Invasion, and Prognosis of Hepatocellular Carcinoma by Targeting GUCD1.
    He Y; He X
    Yonsei Med J; 2019 Mar; 60(3):267-276. PubMed ID: 30799589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
    Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
    Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
    EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma.
    Tanaka S; Shiraha H; Nakanishi Y; Nishina S; Matsubara M; Horiguchi S; Takaoka N; Iwamuro M; Kataoka J; Kuwaki K; Hagihara H; Toshimori J; Ohnishi H; Takaki A; Nakamura S; Nouso K; Yagi T; Yamamoto K
    Int J Cancer; 2012 Dec; 131(11):2537-46. PubMed ID: 22488108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
    Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
    Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition.
    Yu J; Zhang W; Gao F; Liu YX; Chen ZY; Cheng LY; Xie SF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2014 Apr; 13(2):184-91. PubMed ID: 24686546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malic enzyme 1 induces epithelial-mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma.
    Wen D; Liu D; Tang J; Dong L; Liu Y; Tao Z; Wan J; Gao D; Wang L; Sun H; Fan J; Wu W
    Tumour Biol; 2015 Aug; 36(8):6211-21. PubMed ID: 25753478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells.
    Nagahara T; Shiraha H; Sawahara H; Uchida D; Takeuchi Y; Iwamuro M; Kataoka J; Horiguchi S; Kuwaki T; Onishi H; Nakamura S; Takaki A; Nouso K; Yamamoto K
    Oncol Rep; 2015 Sep; 34(3):1169-77. PubMed ID: 26165819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
    Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
    J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition.
    Li PD; Chen P; Peng X; Ma C; Zhang WJ; Dai XF
    Aging (Albany NY); 2018 Jan; 10(1):115-130. PubMed ID: 29348394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.
    Karaosmanoğlu O; Banerjee S; Sivas H
    Cell Oncol (Dordr); 2018 Aug; 41(4):439-453. PubMed ID: 29858962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
    Jin Y; Wang J; Han J; Luo D; Sun Z
    Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN.
    Zhang QY; Men CJ; Ding XW
    J Cell Biochem; 2019 Sep; 120(9):14885-14898. PubMed ID: 31044454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.